

(Translation)

January 25, 2024

Company name: Riken Vitamin Co., Ltd.
Name of representative: Kazuhiko Yamaki
President and Representative Director
(Securities code: 4526; Tokyo Stock
Exchange Prime Market)
Inquiries: Yuichi Nakagawa
General Manager of Corporate Planning
Department, Chief Manager of Corporate
Planning Division
(Tel: 03-5362-1315)

Notice Regarding Recording of Extraordinary Income (Gain on Sale of Investment Securities)

Riken Vitamin Co., Ltd. (the "Company") hereby announces that it has recorded extraordinary income (gain on sale of investment securities) due to the sale of some investment securities, as follows.

1. Reason for the sale of investment securities

To reduce cross-shareholdings.

2. Details of the gain on sale of investment securities

- | | |
|--|--|
| (1) Shares sold: | Securities of one listed company held by the Company |
| (2) Date of sale: | January 25, 2024 |
| (3) Gain on sale of investment securities: | ¥1,895 million |

3. Outlook

The above gain on sale of investment securities will be recorded as extraordinary income in the fourth quarter ending March 31, 2024. The impact of this matter on the Company's consolidated financial results for the current fiscal year is currently under scrutiny, including recent business performance trends. If it becomes necessary to revise the earnings forecast, we will announce it promptly.